Fabrizio Tundo

Fabrizio Tundo

Auto-generated profile, based on publicly available information

Fabrizio Tundo

Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS , Via Carlo Parea 4, 20138 Milan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
ARAntonio Dello Russo
Antonio Dello Russo
CTClaudio Tondo
Claudio Tondo
SBStefano Bianchi
Stefano Bianchi
VSVincenzo Schillaci
Vincenzo Schillaci
Saverio IacopinoSaverio Iacopino
Saverio Iacopino
FSFrancesco Solimene
Francesco Solimene
Background: There is no evidence evaluating efficiency, effectiveness, and safety outcomes in older patients in the context of pulsed‐field ablation technology for the ablation of atrial fibrillation. We aimed to compare safety, efficacy, and acute and long‐term outcomes of pulsed‐field ablation in older patients (≥75 years) with younger ones. Methods: We enrolled consecutive patients who had undergone atrial fibrillation ablation with the pulsed‐field ablation FARAPULSE system (Boston Scientific) at 15 centers. Patients were stratified by age (<65, 65–74, and ≥75 years) and efficacy and safety profiles of these groups were compared. Results: A total of 1082 patients were included: 108 (10%) were ≥75 years old, 374 (34.6%) were 65–74 years old and 600 (55.4%) were <65 years old. Older patients displayed a more pronounced risk profile compared with their younger counterparts, characterized by a significant higher burden of comorbidities. No differences in terms of procedural metrics were found. Pulmonary vein isolation was achieved in all patients. An overall low rate of procedural‐related complications was reported (3.0%) without difference between young and older patients ( P =0.241). During a mean follow‐up of 342±111 days, a primary efficacy end point occurred in 605 of 748 (80.9%) patients with available outcome information. The arrhythmia recurrence rate ranged from 14.4% in patients <65 years old to 26.9% of older patients ( P =0.011). Conclusions: Drawing from these findings, using the FARAPULSE system for atrial fibrillation ablation in older patients demonstrated swift, safe, and effective acute outcomes, mirroring a comparable pattern observed in younger patients and recurrence rates in line with the literature in older patients. Registration: URL: clinicaltrials.gov ; Unique Identifier: NCT05617456.

2 May 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
SMSchiavone Marco
Schiavone Marco
AGAlessio Gasperetti
Alessio Gasperetti
JVJulia Vogler
Julia Vogler
Paolo CompagnucciPaolo Compagnucci
Paolo Compagnucci
MLMikael Laredo
Mikael Laredo
GFGiovanni Battista Forleo
Giovanni Battista Forleo
Women have been historically underrepresented in implantable cardioverter-defibrillator (ICD) trials. No data on sex differences regarding subcutaneous ICDs (S-ICD) carriers have been described. Aim of our study was to investigate sex-related differences among unselected S-ICD recipients. Consecutive patients enrolled in the multicentre, international i-SUSI registry were analysed. Comparisons between sexes were performed using a 1:1 propensity matching adjusted analysis for age, body mass index (BMI), left ventricular function, and substrate. The primary outcome was the rate of appropriate shocks during follow-up. Inappropriate shocks and other device-related complications were deemed secondary outcomes. A total of 1698 patients were extracted from the i-SUSI registry; 399 (23.5%) were females. After propensity matching, two cohorts of 374 patients presenting similar baseline characteristics were analysed. Despite similar periprocedural characteristics and a matched BMI, women resulted at lower risk of conversion failure as per PRAETORIAN score (73.4% vs. 81.3%, P = 0.049). Over a median follow-up time of 26.5 [12.7–42.5] months, appropriate shocks were more common in the male cohort (rate/year 3.4% vs. 1.7%; log-rank P = 0.049), while no significant differences in device-related complications (rate/year: 6.3% vs. 5.8%; log-rank P = 0.595) and inappropriate shocks (rate/year: 4.3% vs. 3.1%; log-rank P = 0.375) were observed. After controlling for confounders, sex remained significantly associated with the primary outcome (aHR 1.648; CI 0.999–2.655, P = 0.048), while not resulting predictor of inappropriate shocks and device-related complications. In a propensity-matched cohort of S-ICD recipients, women are less likely to experience appropriate ICD therapy, while not showing higher risk of device-related complications. ClinicalTrials.gov Identifier: NCT0473876.

22 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SMSchiavone Marco
Schiavone Marco
GFGaetano Fassini
Gaetano Fassini
MMMassimo Moltrasio
Massimo Moltrasio
BMBenedetta Majocchi
Benedetta Majocchi
FTFabrizio Tundo
Fabrizio Tundo
CTClaudio Tondo
Claudio Tondo
(1) Background/Objective Balloon-guided catheter ablation (CA) has emerged as an alternative option for atrial fibrillation (AF) management. The recent introduction of a novel-size adjustable second-generation cryoballoon (CB) system offers innovations, but clinical outcomes remain unexplored. This study aims to assess the acute performance of the POLARx FIT™ CB system in AFCA. (2) Methods: Consecutive patients undergoing AF ablation with the POLARx FIT™ CB system in our center were included. The primary outcome was the rate of 31 mm balloon-size utilization, with secondary outcomes including acute pulmonary vein isolation (PVI) rate, periprocedural complications, and in-hospital AF recurrences. (3) Results: Twenty-four patients with a mean age of 59.5 years, predominantly male (87.5%), and exhibiting paroxysmal AF (91.7%) were enrolled. Procedural characteristics demonstrated a high acute success rate (100% PV isolation) with a favorable safety profile. Notably, the 31 mm CB configuration was utilized in 51% of applications, showcasing its adaptability in challenging anatomies. No major complications occurred, with two patients experiencing in-hospital self-limiting AF recurrences. (4) Conclusions: This study represents the first comprehensive assessment of the POLARx FIT™ CB system in AF ablation. While acknowledging the study’s limitations, this novel CB emerges as a promising tool, warranting further exploration in larger studies with extended follow-up periods.

Verified
Journal Article
Open access
PDF file
MLMelania Lippi
Melania Lippi
AMAngela Serena Maione
Angela Serena Maione
MCMattia Chiesa
Mattia Chiesa
GPGianluca Lorenzo Perrucci
Gianluca Lorenzo Perrucci
LILara Iengo
Lara Iengo
Elena SommarivaElena Sommariva
Elena Sommariva
Arrhythmogenic cardiomyopathy (ACM) is a genetic disorder characterized by ventricular arrhythmias, contractile dysfunctions and fibro-adipose replacement of myocardium. Cardiac mesenchymal stromal cells (CMSCs) participate in disease pathogenesis by differentiating towards adipocytes and myofibroblasts. Some altered pathways in ACM are known, but many are yet to be discovered. We aimed to enrich the understanding of ACM pathogenesis by comparing epigenetic and gene expression profiles of ACM-CMSCs with healthy control (HC)-CMSCs. Methylome analysis identified 74 differentially methylated nucleotides, most of them located on the mitochondrial genome. Transcriptome analysis revealed 327 genes that were more expressed and 202 genes that were less expressed in ACM- vs. HC-CMSCs. Among these, genes implicated in mitochondrial respiration and in epithelial-to-mesenchymal transition were more expressed, and cell cycle genes were less expressed in ACM- vs. HC-CMSCs. Through enrichment and gene network analyses, we identified differentially regulated pathways, some of which never associated with ACM, including mitochondrial functioning and chromatin organization, both in line with methylome results. Functional validations confirmed that ACM-CMSCs exhibited higher amounts of active mitochondria and ROS production, a lower proliferation rate and a more pronounced epicardial-to-mesenchymal transition compared to the controls. In conclusion, ACM-CMSC-omics revealed some additional altered molecular pathways, relevant in disease pathogenesis, which may constitute novel targets for specific therapies.

1 August 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
MMMassimo Moltrasio
Massimo Moltrasio
RSRita Sicuso
Rita Sicuso
FTFabrizio Tundo
Fabrizio Tundo
CTClaudio Tondo
Claudio Tondo
Background: A new intracardiac leadless pacemaker (ILP) has been developed to ensure atrioventricular (AV) synchrony (AVS) during ventricular pacing (VP). Recent studies have shown the feasibility and safety of accelerometer-based atrial sensing and an improvement in AVS among patients with atrioventricular block implanted with the Micra AV ILP (Medtronic Inc., Minneapolis, MN, USA). However, no data exists about the benefits of a VDD ILP in patients wearing a still working VVI Nanostim ILP (St Jude Medical, St Paul, MN, USA). We describe the feasibility of the procedure and the absence of device-related adverse events in the short-term follow-up. Case summary: We present the case of a 72-year-old man implanted with a VVI ILP (Nanostim, St Jude Medical, St Paul, MN, USA) on May 2014, who has developed symptomatic high percentage of VVI asynchronous pacing and was treated with an upgrade to synchronous AV pacemaker (PM) ILP—Micra AV (Medtronic Inc., Minneapolis, MN, USA), which has improved symptoms and functional class. Discussion: Intracardiac leadless pacemakers represent the best current option for patients requiring PM implantation who are at high risk of infection and bleeding. Our case shows that the new AVS ILP is a good alternative to VVI ILP in patients with sinus rhythm and a strong need for VP.

9 September 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
MMMassimo Moltrasio
Massimo Moltrasio
AKAdriano Nunes Kochi
Adriano Nunes Kochi
GFGaetano Fassini
Gaetano Fassini
SRStefania Riva
Stefania Riva
FTFabrizio Tundo
Fabrizio Tundo
CTClaudio Tondo
Claudio Tondo